Case Reports in Neurological Medicine

Case Reports in Neurological Medicine / 2015 / Article

Case Report | Open Access

Volume 2015 |Article ID 171509 |

Mutahir A. Tunio, Mushabbab Al Asiri, Khalid Hussain AL-Qahtani, Wafa AlShakweer, "Cerebellum as Initial Site of Distant Metastasis from Papillary Carcinoma of Thyroid: Review of Three Cases", Case Reports in Neurological Medicine, vol. 2015, Article ID 171509, 5 pages, 2015.

Cerebellum as Initial Site of Distant Metastasis from Papillary Carcinoma of Thyroid: Review of Three Cases

Academic Editor: N. Scott Litofsky
Received13 Feb 2015
Accepted27 Apr 2015
Published06 May 2015


Background. The cerebellum as initial site of distant metastasis from differentiated thyroid carcinoma (DTC) including papillary (PTC) and follicular thyroid carcinoma (FTC) is rare manifestation. Case Presentations. Herein, we present three cases of cerebellar metastasis (CBM) of PTC. Mean age of patients was 67 years (range: 64–72), and mean duration between initial diagnosis and CBM was 49.6 months (range: 37–61). Frequent location was left cerebellar hemisphere and was associated with hydrocephalus. All patients underwent suboccipital craniectomy, and in two patients postoperative intensity modulated radiation therapy (IMRT) was given to deliver 5000 cGy in 25 fractions to residual lesions. Patient without postoperative IMRT had cerebellar recurrence along with lung and bone metastasis after 38 months. However, two patients were found alive and free of disease at the time of last follow-up. Conclusion. CBM from PTC is a rare clinical entity and is often associated with hydrocephalus. Histopathological diagnosis is important to initiate effective treatment, which relies on multidisciplinary approach to prolong the disease-free and overall survival rates.

1. Introduction

Differentiated thyroid carcinoma (DTC), especially papillary thyroid carcinoma (PTC), commonly metastasizes to regional lymph nodes, lungs, and bones. However, the brain is an uncommon site of metastasis, being found only in 0.15% to 1.3% of cases [1]. Moreover; cerebellar metastases (CBM) from PTC are exceptional; only thirteen reported cases of cerebellar metastasis from PTC have been published so far [2]. Symptoms of CBM may vary from asymptomatic to cerebellar dysfunction and stroke. CBM is considered as indicator of poor prognosis [3].

Herein, we describe and discuss the signs and symptoms, diagnostic work-up, differential diagnosis, and management in three cases of CBM from PTC.

2. Case 1

A 72-year-old Saudi female known to be diabetic and hypertensive underwent total thyroidectomy, followed by radioactive iodine (RAI) ablation of 150 millicuries (mCi) under a diagnosis of PTC, follicular variant (pT2N1aM0), in October 2005. Patient was in complete remission and was taking thyroid replacement therapy with 175 micrograms (μg) of L-thyroxine. In February 2010, she presented with three-month history of headaches, vomiting, and gait ataxia. Pertinent neurological findings were dysmetria and dysdiadochokinesia. Stimulated serum thyroglobulin level was raised (51.7 μg/L) with normal antithyroid antibodies. On I-131 whole body scintigraphy (WBS), no foci of abnormal tracer uptake were seen. Magnetic resonance imaging (MRI) of brain revealed a lobulated heterogeneous mass involving the medial left cerebellar hemisphere, measuring 4.0 × 3.5 × 2.5 cm. The mass was associated with surrounding edema, crossing the midline to the right cerebellar hemisphere and compressing the fourth ventricle (Figure 1). Differential diagnosis included a high grade glioma or metastasis. Subsequently, the patient underwent a left suboccipital craniectomy and complete resection of the cerebellar mass. Histopathology revealed papillary fronds with fibrovascular core lined by cuboidal tumor cells, with inclusion bodies (Figure 2). Immunohistochemistry was positive for cytokeratin (CK19), thyroid transcription factor (TTF-1), and thyroglobulin. These findings confirmed the diagnosis of metastatic PTC, follicular variant. The postoperative course was uneventful, and the patient was kept on follow-up, without any adjuvant treatment. In September 2012, she developed recurrence of cerebellar mass, along with new development of bilateral lungs and bone metastases, for which she was treated with palliative radiotherapy to posterior fossa and the right 7th rib followed by 150 mCi RAI ablation. Six months later, the patient died of progressive disease.

3. Case 2

A 64-year-old Saudi male had been diagnosed with PTC in July 2009 and underwent total thyroidectomy. The tumor size was 2.5 × 3 cm and histopathological variant was tall cell PTC with extrathyroid extension; however no lymphovascular space invasion or lymph node metastases were noted. Final pathological TNM classification was T3N0 M0. After RAI ablation of 100 mCi, the patient was kept on follow-up. In August 2012, he started complaints of headaches and inability to walk. Serum TG level was 3290 μg/L ↑. Neurological examination revealed bilateral papilledema and cerebellar signs on the left side. Computed tomography of brain showed a 3.2 × 3.7 cm homogeneous contrast enhancing mass in the inferior vermis with extension into the left cerebellar hemisphere and brainstem causing hydrocephalus (Figure 3). WBS showed intense uptake in both lungs. Patient underwent suboccipital craniectomy and subtotal resection of the mass. Histopathological examination of biopsied lesion revealed tall papillary cells, that is, height at least twice or thrice their width (Figure 4), and positive immunostaining for TTF-1 and CK19 confirmed the diagnosis of metastatic PTC, tall cell variant. Postoperatively, the lesion was treated with IMRT dose of 50 Gy in 25 fractions without any grade 3 toxicity, followed by RAI ablation dose of 150 mCi. At 30 months of follow-up, patient was found alive with stable lung metastasis, decreasing TG level (540 μg/L) without any recurrence in the cerebellum.

4. Case 3

A 65-year-old Saudi female underwent total thyroidectomy for multifocal PTC, classic variant (pT3N1bM0), followed by RAI ablation of 150 mCi in April 2008. Patient remained in complete remission and was on thyroid replacement therapy with 150 μg L-thyroxine. In May 2013, she presented with 4-month history of vertigo, headaches, ataxic gait, and increased tiredness. Serum TG level was moderately elevated (77 μg/L). MRI brain revealed a 4 × 4 cm heterogeneous mass in left cerebellar hemisphere associated with edema (Figure 5). Patient underwent suboccipital craniectomy and subtotal resection of the mass. Histopathological and immunostaining examination of biopsied lesion confirmed the diagnosis of metastatic PTC, classic variant (Figure 6). Postoperative IMRT of dose 50 Gy in 25 fractions was given to the tumor, without any grade 3 toxicity, followed by RAI ablation dose of 150 mCi. At 20 months of follow-up, patient was found alive without any evidence of recurrent or metastatic disease.

5. Discussion

CBM as initial manifestation of distant metastasis from PTC is rare. To date, only thirteen cases of CBM from PTC have been published (Table 1) [112]. In agreement with previously reported cases, CBM cases in our series were seen during the sixth and seventh decades of life with mean age of 67 years (range: 64–72), and mean duration between initial diagnosis and CBM was 49.6 months (range: 37–61) [1, 2, 46]. In our series, one patient with aggressive variant of PTC (tall cell) was identified. Tall cell variant PTC is known to have worse prognosis than classic PTC, and patients with these variants should be treated aggressively with thyroidectomy, neck dissection, and RAI, regardless of tumor size [13].

Reference Age (years)/sexSymptoms Location Treatment Status Follow-up

Tanaka et al. [1]65/FLateral gazing nystagmus and slurred speechLeft cerebellar hemisphere with intratumoral hemorrhage Subtotal resection
Gamma knife surgery 15 Gy
Alive and disease-free23 months

Cha et al. [2]78/FLeft cerebellar hemisphereSubtotal resection
Gamma knife surgery 15 Gy
Alive and disease-free36 months

Aguiar et al. [3]33/FRaised ICPRight cerebellar hemisphere + cerebral lesionsSubtotal resection
Radiation 40 Gy/20 fractions
At 12 months, developed frontal lobe metastasis
Treated with surgery
At 36 months, alive and disease-free
36 months

Lecumberri et al. [4]65/FSurgery and radiotherapyAt 48 months, developed cerebellar recurrence with intratumoral hemorrhage
Treated with surgery
84 months

Pazaitou-Panayiotou et al. [5]69/MDizziness, headaches, and ataxia Right cerebellar hemisphereSubtotal resection and RT 39 Gy/13 fractionsDead with disease4 months

Al-Dhahri et al. [6]75/FDizziness, headache, and vomitingComplete resection and RAI

Carcangiu et al. [7]50/FRight cerebellar hemisphereComplete resection and RAIAlive and disease-free96 months

Honma et al. [8]60/MIncidentalRight cerebellar hemisphereSurgeryAlive and disease-free24 months

Xu et al. [9]IncidentalRight cerebellar hemisphereSurgery

Lin et al. [10]Two casesHeadaches, ataxia, and vomiting Case 1: bilateral cerebellar hemispheres with obstructive hydrocephalus
Case 2: left cerebellar hemisphere
Complete resection

Jyothirmayi et al. [11]Headache, ataxia Left cerebellar hemisphereComplete resection

Pacak et al. [12]Complete resection

Diagnosis of CBM is challenging, as these lesions are often mistaken as chordoma, chondrosarcomas, meningioma, or schwannoma on CT and MRI imaging [47]. Histopathological diagnosis along with immunohistochemistry should be made in such cases for definitive diagnosis. All of our patients underwent suboccipital craniectomies, without any postoperative morbidity. However, complete surgical resection is often difficult in such cases because of presence of adjacent vital structures (brainstem, cochlea, and cranial nerves), risk of cerebrospinal fluid leak, and bleeding. In our series, only one patient had complete resection, followed by RAI ablation [612]. For such lesions, postoperative radiation therapy shall be offered, as one patient in our series developed cerebellar metastasis recurrence after surgery alone. With advent of novel techniques in radiation therapy (IMRT, protons, carbon ions, and stereotactic radiosurgery), it is now possible to give high dose to unresectable or residual tumor, to achieve better local control without any serious acute toxicities as seen in our patients [15].

Presence of CBM is generally considered as poor prognostic factor; however, in our patients, the median survival was 37 months (range: 21–60), which was found to be in agreement with literature [14, 6, 7].

In conclusion, cerebellar metastasis from PTC is a rare clinical entity and is often associated with hydrocephalus. Surgical resection followed by postoperative radiotherapy and RAI ablation is the treatment of choice. However, for such cases, multidisciplinary approach can prolong the disease-free and overall survival rates in PTC patients.

Written consent was taken from guardian and patients for publication.

Conflict of Interests

No potential conflict of interests among authors.


  1. T. Tanaka, N. Kato, K. Aoki et al., “Cerebellar hemorrhage secondary to cerebellopontine angle metastasis from thyroid papillary carcinoma,” Neurologia Medico-Chirurgica, vol. 53, no. 4, pp. 233–236, 2013. View at: Publisher Site | Google Scholar
  2. S. T. Cha, R. Jarrahy, R. A. Mathiesen, R. Suh, and H. K. Shahinian, “Cerebellopontine angle metastasis from papillary carcinoma of the thyroid: case report and literature review,” Surgical Neurology, vol. 54, no. 4, pp. 320–326, 2000. View at: Publisher Site | Google Scholar
  3. P. H. Aguiar, C. Agner, F. R. Tavares, and N. Yamaguchi, “Unusual brain metastases from papillary thyroid carcinoma: case report,” Neurosurgery, vol. 49, no. 4, pp. 1008–1013, 2001. View at: Google Scholar
  4. B. Lecumberri, C. Álvarez-Escolá, P. Martín-Vaquero et al., “Solitary hemorrhagic cerebellar metastasis from occult papillary thyroid microcarcinoma,” Thyroid, vol. 20, no. 5, pp. 563–567, 2010. View at: Publisher Site | Google Scholar
  5. K. Pazaitou-Panayiotou, A. Kaprara, A. Chrisoulidou et al., “Cerebellar metastasis as first metastasis from papillary thyroid carcinoma,” Endocrine Journal, vol. 52, no. 6, pp. 653–657, 2005. View at: Publisher Site | Google Scholar
  6. S. F. Al-Dhahri, A. S. Al-Amro, W. Al-Shakwer, and A. S. Terkawi, “Cerebellar mass as a primary presentation of papillary thyroid carcinoma: case report and literature review,” Head & Neck Oncology, vol. 1, article 23, 2009. View at: Publisher Site | Google Scholar
  7. M. L. Carcangiu, G. Zampi, A. Pupi, A. Castagnoli, and J. Rosai, “Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy,” Cancer, vol. 55, no. 4, pp. 805–828, 1985. View at: Publisher Site | Google Scholar
  8. Y. Honma, K. Kawakita, and S. Nagao, “Intramedullary spinal cord and brain metastases from thyroid carcinoma detected 11 years after initial diagnosis: case report,” Neurologia Medico-Chirurgica, vol. 36, no. 8, pp. 593–597, 1996. View at: Publisher Site | Google Scholar
  9. Y.-H. Xu, H.-J. Song, Z.-L. Qiu, and Q.-Y. Luo, “Brain metastases with exceptional features from papillary thyroid carcinoma: report of three cases,” Hellenic Journal of Nuclear Medicine, vol. 14, no. 1, pp. 56–59, 2011. View at: Google Scholar
  10. C. K. Lin, A. S. Lieu, and S. L. Howng, “Hemorrhagic cerebellar metastasis from papillary thyroid carcinoma,” Kaohsiung Journal of Medical Sciences, vol. 15, no. 4, pp. 234–238, 1999. View at: Google Scholar
  11. R. Jyothirmayi, J. Edison, P. P. Nayar, M. K. Nair, and B. Rajan, “Brain metastases from papillary carcinoma thyroid,” British Journal of Radiology, vol. 68, no. 811, pp. 767–769, 1995. View at: Publisher Site | Google Scholar
  12. K. Pacak, D. C. Sweeney, L. Wartofsky et al., “Solitary cerebellar metastasis from papillary thyroid carcinoma: a case report,” Thyroid, vol. 8, no. 4, pp. 327–335, 1998. View at: Publisher Site | Google Scholar
  13. H. S. Kazaure, S. A. Roman, and J. A. Sosa, “Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients,” Annals of Surgical Oncology, vol. 19, no. 6, pp. 1874–1880, 2012. View at: Publisher Site | Google Scholar

Copyright © 2015 Mutahir A. Tunio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1030 Views | 368 Downloads | 0 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.